Age, Biography and Wiki
Shinya Yamanaka was born on 4 September, 1962 in Higashiosaka, Osaka, Japan. Discover Shinya Yamanaka’s Biography, Age, Height, Physical Stats, Dating/Affairs, Family and career updates. Learn How rich is He in this year and how He spends money? Also learn how He earned most of networth at the age of 58 years old?
|Age||58 years old|
|Born||4 September 1962|
|Birthplace||Higashiosaka, Osaka, Japan|
We recommend you to check the complete list of Famous People born on 4 September.
He is a member of famous with the age 58 years old group.
Shinya Yamanaka Height, Weight & Measurements
At 58 years old, Shinya Yamanaka height not available right now. We will update Shinya Yamanaka’s Height, weight, Body Measurements, Eye Color, Hair Color, Shoe & Dress size soon as possible.
|Body Measurements||Not Available|
|Eye Color||Not Available|
|Hair Color||Not Available|
Who Is Shinya Yamanaka’s Wife?
His wife is Chika Yamanaka
Shinya Yamanaka Net Worth
He net worth has been growing significantly in 2018-19. So, how much is Shinya Yamanaka worth at the age of 58 years old? Shinya Yamanaka’s income source is mostly from being a successful . He is from Japan. We have estimated Shinya Yamanaka’s net worth, money, salary, income, and assets.
|Net Worth in 2020||$1 Million – $5 Million|
|Salary in 2019||Under Review|
|Net Worth in 2019||Pending|
|Salary in 2019||Under Review|
|Source of Income|
Shinya Yamanaka Social Network
|Wikipedia||Shinya Yamanaka Wikipedia|
Timeline of Shinya Yamanaka
6. Can medically use iPS cells from patients with genetic and other disorders to gain insights into the disease process. – Amyotrophic lateral sclerosis (ALS), Rett syndrome, spinal muscular atrophy (SMA), α1-antitrypsin deficiency, familial hypercholesterolemia and glycogen storage disease type 1A. – For cardiovascular disease, Timothy syndrome, LEOPARD syndrome, type 1 and 2 long QT syndrome – Alzheimer’s, Spinocerebellar ataxia, Huntington’s etc.
Yamanaka’s research has “opened a new door and the world’s scientists have set forth on a long journey of exploration, hoping to find our cells’ true potential.”
In July 2014, a scandal regarding the research of Haruko Obokata was connected to Yamanaka. He could not find the lab notes from the period in question and was made to apologise.
In 2013, iPS cells were used to generate a human vascularized and functional liver in mice in Japan. Multiple stem cells were used to differentiate the component parts of the liver, which then self-organized into the complex structure. When placed into a mouse host, the liver vessels connected to the hosts vessels and performed normal liver functions, including breaking down of drugs and liver secretions.
The 2012 Nobel Prize in Physiology or Medicine was awarded jointly to Sir John B. Gurdon and Shinya Yamanaka “for the discovery that mature cells can be reprogrammed to become pluripotent.”
In June 2012, he was awarded the Millennium Technology Prize for his work in stem cells. He shared the 1.2 million euro prize with Linus Torvalds, the creator of the Linux kernel. In October 2012, he and fellow stem cell researcher John Gurdon were awarded the Nobel Prize in Physiology or Medicine “for the discovery that mature cells can be reprogrammed to become pluripotent.”
Yamanaka has been listed as one of the 15 Asian Scientists To Watch by Asian Scientist magazine on May 15, 2011. In June 2011, he was awarded the inaugural McEwen Award for Innovation; he shared the $100,000 prize with Kazutoshi Takahashi, who was the lead author on the paper describing the generation of induced pluripotent stem cells.
Yamanaka practiced judo (2nd Dan black belt) and played rugby as a university student. He also has a history of running marathons. After a 20-year gap, he competed in the inaugural Osaka Marathon in 2011 as a charity runner with a time of 4:29:53. He took part in Kyoto Marathon to raise money for iPS research since 2012. His personal best is 3:25:20 at 2018 Beppu-Ōita Marathon.
He received the 2010 BBVA Foundation Frontiers of Knowledge Award in the biomedicine category, the 2011 Wolf Prize in Medicine with Rudolf Jaenisch, and the 2012 Millennium Technology Prize together with Linus Torvalds. In 2012 he and John Gurdon were awarded the Nobel Prize for Physiology or Medicine for the discovery that mature cells can be converted to stem cells. In 2013 he was awarded the $3 million Breakthrough Prize in Life Sciences for his work.
In May 2010, Yamanaka was given “Doctor of Science honorary degree” by Mount Sinai School of Medicine.
In September 2010, he was awarded the Balzan Prize for his work on biology and stem cells.
Moreover, in 2007, Yamanaka and his colleagues found iPS cells with germ line transmission (via selecting for Oct4 or Nanog gene). Also in 2007, they were the first to produce human iPS cells.
In 2007, Yamanaka was recognized as a “Person Who Mattered” in the Time Person of the Year edition of Time Magazine. Yamanaka was also nominated as a 2008 Time 100 Finalist. In June 2010, Yamanaka was awarded the Kyoto Prize for reprogramming adult skin cells to pluripotential precursors. Yamanaka developed the method as an alternative to embryonic stem cells, thus circumventing an approach in which embryos would be destroyed.
In 2006, he and his team generated induced pluripotent stem cells (iPS cells) from adult mouse fibroblasts. iPS cells closely resemble embryonic stem cells, the in vitro equivalent of the part of the blastocyst (the embryo a few days after fertilization) which grows to become the embryo proper. They could show that his iPS cells were pluripotent, i.e. capable of generating all cell lineages of the body. Later he and his team generated iPS cells from human adult fibroblasts, again as the first group to do so. A key difference from previous attempts by the field was his team’s use of multiple transcription factors, instead of transfecting one transcription factor per experiment. They started with 24 transcription factors known to be important in the early embryo, but could in the end reduce it to 4 transcription factors – Sox2, Oct4, Klf4 and c-Myc.
His wife advised him to become a practicing doctor, but instead he applied for a position at the Nara Institute of Science and Technology. He stated that he could and would clarify the characteristics of embryonic stem cells, and this can-do attitude won him the job. From 1999–2003, he was an associate professor there, and started the research that would later win him the 2012 Nobel Prize. He became a full professor and remained at the institute in that position from 2003–2005. Between 2004 and 2010, Yamanaka was a professor at the Institute for Frontier Medical Sciences. Currently, Yamanaka is the director and a professor at the Center for iPS Cell Research and Application at Kyoto University.
From 1993 to 1996, he was at the Gladstone Institute of Cardiovascular Disease. Between 1996 and 1999, he was an assistant professor at Osaka City University Medical School, but found himself mostly looking after mice in the laboratory, not doing actual research.
Between 1987 and 1989, Yamanaka was a resident in orthopedic surgery at the National Osaka Hospital. His first operation was to remove a benign tumor from his friend Shuichi Hirata, a task he could not complete after one hour when a skilled surgeon would have taken ten minutes or so. Some seniors referred to him as “Jamanaka”, a pun on the Japanese word for obstacle.
Shinya Yamanaka (山中 伸弥 , Yamanaka Shin’ya, born September 4, 1962) is a Japanese stem cell researcher, winner of the Nobel Prize. He serves as the director of Center for iPS Cell (induced Pluripotent Stem Cell) Research and Application and a professor at the Institute for Frontier Medical Sciences at Kyoto University; as a senior investigator at the UCSF-affiliated J. David Gladstone Institutes in San Francisco, California; and as a professor of anatomy at University of California, San Francisco (UCSF). Yamanaka is also a past president of the International Society for Stem Cell Research (ISSCR).
Yamanaka was born in Higashiōsaka, Japan, in 1962. After graduating from Tennōji High School attached to Osaka Kyoiku University, he received his M.D. degree at Kobe University in 1987 and his Ph.D. degree at Osaka City University Graduate School in 1993. After this, he went through a residency in orthopedic surgery at National Osaka Hospital and a postdoctoral fellowship at the J. David Gladstone Institutes of Cardiovascular Disease, San Francisco.
In 1962, John B. Gurdon demonstrated that the nucleus from a differentiated frog intestinal epithelial cell can generate a fully functional tadpole via transplantation to an enucleated egg. Gurdon used somatic cell nuclear transfer (SCNT) as a method to understand reprogramming and how cells change in specialization. He concluded that differentiated somatic cell nuclei had the potential to revert to pluripotency. This was a paradigm shift during the time. It showed that a differentiated cell nucleus has retained the capacity to successfully revert to an undifferentiated state, with the potential to restart development (pluripotent capacity).